Operationalising outpatient antimicrobial stewardship to reduce system-wide antibiotics for acute bronchitis.
PDSA
antibiotic management
audit and feedback
control charts/run charts
quality improvement
Journal
BMJ open quality
ISSN: 2399-6641
Titre abrégé: BMJ Open Qual
Pays: England
ID NLM: 101710381
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
24
11
2020
accepted:
06
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
30
9
2021
Statut:
ppublish
Résumé
Antibiotics are not recommended for treatment of acute uncomplicated bronchitis (AUB), but are often prescribed (85% of AUB visits within the Veterans Affairs nationally). This quality improvement project aimed to decrease antibiotic prescribing for AUB in community-based outpatient centres from 65% to <32% by April 2020. From January to December 2018, community-based outpatient clinics' 6 months' average of prescribed antibiotics for AUB and upper respiratory infections was 63% (667 of 1054) and 64.6% (314 of 486) when reviewing the last 6 months. Seven plan-do-study-act (PDSA) cycles were implemented by an interprofessional antimicrobial stewardship team between January 2019 and March 2020. Balancing measures were a return patient phone call or visit within 4 weeks for the same complaint. Χ The AUB antibiotic prescribing rate decreased from 64.6% (314 of 486) in the 6 months prior to the intervention to 36.8% (154 of 418) in the final 6 months of the intervention. No change was seen in balancing measures. The largest reduction in antibiotic prescribing was seen after implementation of PDSA 6 in which 14 high prescribers were identified and targeted for individualised reviews of encounters of patients with AUB with an antimicrobial steward. Operational implementation of successful stewardship interventions is challenging and differs from the traditional implementation study environment. As a nascent outpatient stewardship programme with limited resources and no additional intervention funding, we successfully reduced antibiotic prescribing from 64.6% to 36.8%, a reduction of 43% from baseline. The most success was seen with targeted education of high prescribers.
Sections du résumé
BACKGROUND
Antibiotics are not recommended for treatment of acute uncomplicated bronchitis (AUB), but are often prescribed (85% of AUB visits within the Veterans Affairs nationally). This quality improvement project aimed to decrease antibiotic prescribing for AUB in community-based outpatient centres from 65% to <32% by April 2020.
METHODS
From January to December 2018, community-based outpatient clinics' 6 months' average of prescribed antibiotics for AUB and upper respiratory infections was 63% (667 of 1054) and 64.6% (314 of 486) when reviewing the last 6 months. Seven plan-do-study-act (PDSA) cycles were implemented by an interprofessional antimicrobial stewardship team between January 2019 and March 2020. Balancing measures were a return patient phone call or visit within 4 weeks for the same complaint. Χ
RESULTS
The AUB antibiotic prescribing rate decreased from 64.6% (314 of 486) in the 6 months prior to the intervention to 36.8% (154 of 418) in the final 6 months of the intervention. No change was seen in balancing measures. The largest reduction in antibiotic prescribing was seen after implementation of PDSA 6 in which 14 high prescribers were identified and targeted for individualised reviews of encounters of patients with AUB with an antimicrobial steward.
CONCLUSIONS
Operational implementation of successful stewardship interventions is challenging and differs from the traditional implementation study environment. As a nascent outpatient stewardship programme with limited resources and no additional intervention funding, we successfully reduced antibiotic prescribing from 64.6% to 36.8%, a reduction of 43% from baseline. The most success was seen with targeted education of high prescribers.
Identifiants
pubmed: 34210668
pii: bmjoq-2020-001275
doi: 10.1136/bmjoq-2020-001275
pmc: PMC8252871
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pain Med. 2011 Oct;12(10):1490-501
pubmed: 21943325
J Infect Dev Ctries. 2014 Feb 13;8(2):129-36
pubmed: 24518621
JAMA. 2016 Feb 9;315(6):562-70
pubmed: 26864410
JAMA. 2013 Jun 12;309(22):2345-52
pubmed: 23757082
Mil Med. 2012 Jan;177(1):23-6
pubmed: 22338974
J Am Board Fam Med. 2018 May-Jun;31(3):417-430
pubmed: 29743225
J Antimicrob Chemother. 2014 Jul;69(7):1748-54
pubmed: 24633207
Scand J Prim Health Care. 2015 Mar;33(1):11-20
pubmed: 25716427
Lancet. 2016 Apr 23;387(10029):1743-52
pubmed: 26898856
Antimicrob Resist Infect Control. 2017 Jan 13;6:11
pubmed: 28101333
BMJ. 2007 Nov 10;335(7627):982
pubmed: 17947744
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Infect Control Hosp Epidemiol. 2016 Jun;37(6):647-54
pubmed: 26905338
BMC Fam Pract. 2018 Jun 23;19(1):96
pubmed: 29933762
Am J Med Qual. 2019 May/Jun;34(3):217-225
pubmed: 30205697
JAMA. 2016 Nov 22;316(20):2115-2125
pubmed: 27893129
Ann Intern Med. 2015 Jul 21;163(2):73-80
pubmed: 26192562
BMC Fam Pract. 2017 Feb 13;18(1):20
pubmed: 28193174
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2008 Sep 15;47(6):744-6
pubmed: 18694343
Infect Control Hosp Epidemiol. 2020 Feb;41(2):135-142
pubmed: 31755401
Am J Infect Control. 2014 Oct;42(10 Suppl):S257-63
pubmed: 25239719
Implement Sci. 2019 May 14;14(1):51
pubmed: 31088483
Cleve Clin J Med. 2017 Sep;84(9):673-679
pubmed: 28885907
JAMA. 2017 Oct 10;318(14):1391-1392
pubmed: 29049577
Antimicrob Agents Chemother. 2019 Dec 20;64(1):
pubmed: 31685466
Clin Infect Dis. 2020 Nov 5;71(8):e316-e322
pubmed: 31813965
Infect Control Hosp Epidemiol. 2014 Oct;35 Suppl 3:S69-78
pubmed: 25222901
JAMA. 2014 Dec 17;312(23):2569-70
pubmed: 25317759
Infect Control Hosp Epidemiol. 2018 Sep;39(9):1108-1111
pubmed: 30115219
J R Soc Med. 2010 May;103(5):178-87
pubmed: 20436026
J Antimicrob Chemother. 2018 Oct 1;73(10):2613-2624
pubmed: 30020464